Stability of Ofloxacin in Peritoneal Dialysis Solutions

  title={Stability of Ofloxacin in Peritoneal Dialysis Solutions},
  author={C Battista and Michael P. Kane and D. G. Moon and George R. Bailie},
  journal={Peritoneal Dialysis International},
  pages={72 - 73}
It is reported that more than 86 000 patients worldwide are undergoing CAPD as a treatment for end-stage renal disease (1). The advantages to the patient of peritoneal dialysis compared with hemodialysis are an increased sense of well-being, freedom from the constraints that are imposed by incenter dialysis, fewer restrictions on fluid intake and diet, increased hemoglobin concentrations, easier management of hypertension, and less day-today fluctuat ion in biochemical variables (2). Despite… Expand

Topics from this paper

Intraperitoneal Administration of Drugs in Peritoneal Dialysis Patients: A Review of Compatibility and Guidance for Clinical Use
A detailed literature search on drug compatibility and stability was performed and results of all published stability studies are presented for all drugs, PD solutions, and containers studied, to aid clinicians managing PD patients. Expand
Peritonitis in Paediatric Continuous Peritoneal Dialysis
The fact that this complication still constitutes one of the main causes of morbidity and technique failure highlights the need for optimal prevention and diagnosis, adequate treatment, and a balance between the goal of obtaining a high primary cure rate and the need to limit treatment side-effects. Expand
Stability of Drug Additives to Peritoneal Dialysate
  • G. Bailie, M. P. Kane
  • Medicine
  • Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis
  • 1995
Drug additives in peritoneal dialysate, singly or combined, should be avoided unless data are available to support their stability, and the practice of preparing numerous bags at one time should be avoid. Expand
Stability of moxifloxacin injection in peritoneal dialysis solution bags (Dianeal PD1 1·36%® and Dianeal PD1 3·86%®)
This study test stability of moxifloxacin in PD solutions stored at different temperatures to find out if the drug is suitable for treating peritonitis in peritoneal dialysis patients. Expand


Current concepts in the management of peritonitis in patients undergoing continuous ambulatory peritoneal dialysis.
If this infection can be successfully managed, CAPD promises to become increasingly popular for the treatment of chronic renal failure. Expand
Peritonitis in continuous ambulatory peritoneal dialysis: analysis of an 8-year experience.
Experiences with peritonitis in a continuous ambulatory peritoneal dialysis (CAPD) program at a single center over 8 years were reviewed and Gram-positive organisms continue to account for most episodes in a similar proportion. Expand
Continuous Ambulatory Peritoneal Dialysis: A Review of its Mechanics, Advantages, Complications, and Areas of Controversy
CAPD is an alternative to hemodialysis for the treatment of endstage renal disease and has many complications, leading to significant morbidity, indicating that CAPD is not appropriate for all patients. Expand
Multiple-Dose-Kinetics of Ofloxacin after Intraperitoneal Application in CAPD Patients
Peritonitis episodes that were caused by Staphylococcus epidermidis and by E. coli were cured in all patients, and no local or systemic adverse events were observed. Expand
A Comparison of Peritoneal Dialysis-Related Infections in Short and Long Term Peritoneal Dialysis Patients 1
Although infection rates are lower in patients on peritoneal dialysis 4 years or more, S. aureus and P. aeruginosa continue to account for a high proportion of the infections. Expand
A randomized prospective trial of three different regimens of treatment of peritonitis in patients on continuous ambulatory peritoneal dialysis.
  • M. Chan, I. Cheng, W. S. Ng
  • Medicine
  • American journal of kidney diseases : the official journal of the National Kidney Foundation
  • 1990
Oral ofloxacin is an acceptable first-line therapy for peritonitis in CAPD patients, andSide effects were minimal with IP treatment and with oral ofl Roxacin, but severe nausea and vomiting occurred in some cases with the combination of ofl Oxacin and rifampicin. Expand
CAPD peritonitis. Incidence, pathogens, diagnosis, and management.
  • M. Saklayen
  • Medicine
  • The Medical clinics of North America
  • 1990
With newer techniques, like Y-connector or ultraviolet light system, the rate of peritonitis has declined; however, it has still remained the major complication of the CAPD program. Expand
Oral treatment of peritonitis in CAPD patients with two dosage regimens of ofloxacin.
Two open studies of oral treatment of peritonitis in CAPD patients with ofloxacin are described and the cure rate was 50% in the first study and 83%" in the second. Expand
Pharmacokinetics of ofloxacin. An overview.
  • S. Flor
  • Medicine
  • The American journal of medicine
  • 1989
Ofloxacin exhibits a pharmacokinetic profile similar to that seen after oral dosing, which supports the almost total oral absorption and the interchangeability of both forms of therapy, and little or no dosage adjustment is necessary. Expand
Ofloxacin. A reappraisal of its antimicrobial activity, pharmacology and therapeutic use.
Ofloxacin offers a valuable oral treatment for use in a wide range of clinical infections, but with a particular advantage in more severe or chronic infections when recourse to parenteral broad spectrum agents would normally be required, thereby providing cost savings and additionally allowing outpatient treatment. Expand